Drug Profile


Alternative Names: CMD-003; Cytorex-EBV; EBV-specific cytotoxic T-lymphocytes - CAGT/Cell Medica; EBV-specific T-cells - CAGT/Cell Medica; Epstein Barr virus antigen-activated T-cells - CAGT/Cell Medica; Epstein Barr virus-specific cytotoxic T-lymphocytes - CAGT/Cell Medica; Epstein Barr virus-specific T-cells - CAGT/Cell Medica

Latest Information Update: 08 Feb 2017

Price : $50

At a glance

  • Originator Baylor College of Medicine
  • Developer Baylor College of Medicine; Cell Medica; Center for Cell and Gene Therapy
  • Class Antineoplastics; Cell therapies; T lymphocyte cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lymphoproliferative disorders; Non-Hodgkin's lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Lymphoma; Nasopharyngeal cancer
  • No development reported Epstein-Barr virus infections

Most Recent Events

  • 06 Dec 2016 Efficacy data from the phase II CITADEL and phase I GRALE trial in Lymphoma presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2016)
  • 01 Nov 2016 Phase-II clinical trials in Lymphoma (In adolescents, In adults, In the elderly) in USA (IV) (NCT02763254)
  • 14 Sep 2016 Cell Medica plans a phase II trial in Lymphomas (In adolescents, In adults, In the elderly) in USA (NCT02763254)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top